

[Budesonide + formoterol](#)

Essential medicine status

Section:

[25. Medicines acting on the respiratory tract](#) [25.1. Antiasthmatic and medicines for chronic obstructive pulmonary disease](#)

ATC codes: [R03AK07](#)

Indication

Asthma ICD11 code: [CA23](#)

INN

Budesonide + formoterol

Medicine type

Chemical agent

List type

Core

Formulations

Respiratory > Inhalation > powder: 100 µg + 6 µg per dose actuation in dry powder inhaler ; 200 µg + 6 µg per dose actuation in dry powder inhaler

EML status history

First added in 2017 ([TRS 1006](#))

Changed in 2021 ([TRS 1035](#))

Changed in 2025 ([TRS 1064](#))

Sex

All

Age

Adolescents and adults

Therapeutic alternatives

[budesonide + salmeterol](#) (ATC codes: [R03AK12](#))

[beclometasone + formoterol](#) (ATC codes: [R03AK08](#))

[mometasone + formoterol](#) (ATC codes: [R03AK09](#))

[fluticasone + formoterol](#) (ATC codes: [R03AK11](#))

[fluticasone furoate + vilanterol](#) (ATC codes: [R03AK10](#))

Patent information

Patents have expired in most jurisdictions

Read more [about patents](#).

Wikipedia

[Budesonide + formoterol](#)

DrugBank

[Budesonide](#) ,

[Formoterol](#)

Summary of evidence and Expert Committee recommendations

Following the review of the age-appropriateness of formulations of essential medicines for children, the Expert Committee recommended the following changes to the listing of budesonide + formoterol on the EML: - update the listing description of inhalation delivery systems for consistency across the Model Lists and to better reflect product characteristics.